Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–76
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Able to comply with the study protocol, in the investigator's judgment
Completion of Study GA30044 up to 48 weeks
Acceptable safety and tolerability during Study GA30044 as determined by the investigator
You may not be if
Met protocol-defined treatment-stopping criteria during Study GA30044
An adverse event in Study GA30044 that required permanent discontinuation of study drug
In the opinion of the investigator, any new, significant, uncontrolled comorbidity or new clinical manifestation (related to SLE or not) that requires medications not allowed in this protocol; or could put the participant at undue risk from a safety perspective
Any uncontrolled or clinically significant laboratory abnormality that would affect safety, interpretation of study data, or the participant's participation in the study in the opinion of the investigator in consultation with the Medical Monitor
Clareo Health | An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
